A Rollover Study of BI 201335 in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-experienced Genotype 1 Hepatitis C Infected Patients
- First Posted Date
- 2011-04-06
- Last Posted Date
- 2016-06-30
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 119
- Registration Number
- NCT01330316
- Locations
- 🇨🇦
1220.48.1007 Boehringer Ingelheim Investigational Site, Victoria, British Columbia, Canada
🇺🇸1220.48.0087 Boehringer Ingelheim Investigational Site, Baton Rouge, Louisiana, United States
🇺🇸1220.48.0027 Boehringer Ingelheim Investigational Site, Framingham, Massachusetts, United States
Drug-drug Interaction of Empagliflozin (BI 10773) and Microgynon
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2011-04-04
- Last Posted Date
- 2014-06-18
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 18
- Registration Number
- NCT01328184
- Locations
- 🇩🇪
1245.41.1 Boehringer Ingelheim Investigational Site, Biberach, Germany
Afatinib (BIBW2992) in HER2 (Human Epidermal Growth Factor Receptor 2)-Overexpressing Inflammatory Breast Cancer
- Conditions
- Breast Neoplasms
- Interventions
- First Posted Date
- 2011-03-29
- Last Posted Date
- 2016-07-19
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 26
- Registration Number
- NCT01325428
- Locations
- 🇹🇳
1200.89.21601 Boehringer Ingelheim Investigational Site, Ariana, Tunisia
🇺🇸1200.89.10005 Boehringer Ingelheim Investigational Site, Durham, North Carolina, United States
🇦🇺1200.89.61002 Boehringer Ingelheim Investigational Site, East Bentleigh, Victoria, Australia
Monotherapy Dose Finding With BI 847325 in Solid Tumours
- Conditions
- Neoplasms
- Interventions
- Drug: day 1 to day 14Drug: day 1 to day 5
- First Posted Date
- 2011-03-29
- Last Posted Date
- 2018-12-21
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 69
- Registration Number
- NCT01324830
- Locations
- 🇧🇪
1287.1.3201 Boehringer Ingelheim Investigational Site, Bruxelles, Belgium
🇧🇪1287.1.3202 Boehringer Ingelheim Investigational Site, Leuven, Belgium
Trial to Determine MTD of BI 836845 Administered Intravenously Once Every Three Weeks in Patients With Advanced Solid Tumours and Later a Weekly Dosing Schedule in Selected Tumour Types
- First Posted Date
- 2011-03-17
- Last Posted Date
- 2016-05-30
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 64
- Registration Number
- NCT01317420
- Locations
- 🇬🇧
1280.2.4401 Boehringer Ingelheim Investigational Site, Sutton, United Kingdom
🇬🇧1280.2.4402 Boehringer Ingelheim Investigational Site, Leeds, United Kingdom
Twynsta Study With Lifestyle Modifications in Korean Patients With Hypertension
- First Posted Date
- 2011-03-16
- Last Posted Date
- 2015-09-21
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 2089
- Registration Number
- NCT01316419
- Locations
- 🇰🇷
Boehringer Ingelheim Investigational Site 51, Jeju, Korea, Republic of
🇰🇷Boehringer Ingelheim Investigational Site 54, Chonbuk, Korea, Republic of
🇰🇷Boehringer Ingelheim Investigational Site 55, Busan, Korea, Republic of
Efficacy and Safety of 2 Doses of Tiotropium Via Respimat in Adult Patients With Mild Persistent Asthma
- Conditions
- Asthma
- Interventions
- First Posted Date
- 2011-03-16
- Last Posted Date
- 2015-04-15
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 465
- Registration Number
- NCT01316380
- Locations
- 🇦🇷
205.442.54003 Boehringer Ingelheim Investigational Site, Florencio Varela, Argentina
🇬🇹205.442.50203 Boehringer Ingelheim Investigational Site, Guatemala, Guatemala
🇦🇷205.442.54002 Boehringer Ingelheim Investigational Site, Capital Federal, Argentina
Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Empagliflozin in Chinese Female and Male Patients With Type 2 Diabetes Mellitus
- First Posted Date
- 2011-03-16
- Last Posted Date
- 2014-06-17
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 24
- Registration Number
- NCT01316341
- Locations
- 🇨🇳
1245.44.86001 Boehringer Ingelheim Investigational Site, Beijing, China
BIBF 1120 + Carboplatin/Pegylated Liposomal Doxorubicin (PLD) in Patients With Advanced Ovarian Cancer, Fallopian Tube Carcinoma or Primary Peritoneal Cancer
- Conditions
- Ovarian NeoplasmsPeritoneal Neoplasms
- Interventions
- Drug: BIBF 1120 + PLD 30 mg/m2 + CBDCA AUC5 mg/mL*minDrug: BIBF 1120+ PLD 30 mg/m2 + CBDCA AUC5 mg/mL*min
- First Posted Date
- 2011-03-14
- Last Posted Date
- 2025-02-13
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 19
- Registration Number
- NCT01314105
- Locations
- 🇪🇸
Hospital Vall d'Hebron, Barcelona, Spain
🇪🇸Hospital Clínic de Barcelona, Barcelona, Spain
🇪🇸Hospital Duran i Reynals, L'Hospitalet de Llobregat, Spain
A Study to Compare the Efficacy and Safety of Different Dosings of Olodaterol Administered With the Respimat® Inhaler in Patients With Moderate to Severe Asthma
- Conditions
- Asthma
- Interventions
- First Posted Date
- 2011-03-09
- Last Posted Date
- 2014-05-01
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 206
- Registration Number
- NCT01311661
- Locations
- 🇩🇪
1222.29.49006 Boehringer Ingelheim Investigational Site, Berlin, Germany
🇺🇸1222.29.11012 Boehringer Ingelheim Investigational Site, Wheat Ridge, Colorado, United States
🇭🇺1222.29.36003 Boehringer Ingelheim Investigational Site, Nyiregyhaza, Hungary